Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Interest Expense

Cost of servicing the company's debt during the period.

Immunome, Inc.NASDAQ: IMNM

Interest Expense · Q3 FY2026 · quarter ended Sep 2026

Interest expense remains negative

Q3 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How IMNM compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
IMNM Competitors
Interest Expense for IMNM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$39.85M USD+9.8%+125.2%40.0%
MGNXMacroGenics, Inc.LTM Mar 2026$13.31M USD+13616.5%—8.5%
IMCRImmunocore Holdings plcLTM Mar 2026$11.49M USD-34.5%+31.0%3.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$1.78M USD———
IMTXImmatics N.V.LTM Mar 2026€909K EUR-3.5%-3.0%2.4%
BCYCBicycle Therapeutics plcLTM Mar 2026$203K USD-78.9%-60.5%0.3%
IMNMImmunome, Inc.LTM Sep 2026$0 USD———
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$0 USD——0.0%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD———
Peer median (excluding IMNM) —-3.5%+14.0%2.7%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.